(IONS) Ionis Pharmaceuticals - Ratings and Ratios
Triglyceride,Neuromuscular,ADS,ATTR,TTR
IONS EPS (Earnings per Share)
IONS Revenue
Description: IONS Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company that specializes in developing RNA-targeted medicines. The companys product portfolio includes several approved treatments for rare and severe diseases, such as familial chylomicronemia syndrome, hereditary transthyretin-mediated amyloidosis, and spinal muscular atrophy. Key products include TRYNGOLZA, WAINUA, SPINRAZA, QALSODY, TEGSEDI, and WAYLIVRA.
The companys pipeline is robust, with several products in Phase 3 clinical trials, including Olezarsen for hypertriglyceridemia and cardiovascular disease, Donidalorsen for hereditary angioedema, and Zilganerse for Alexander disease. Additionally, ION582 has completed Phase 2 clinical trials for the treatment of Angelman syndrome. Other mid-stage pipeline investigational medicines include Eplontersen, Pelacarsen, Bepirovirsen, Sefaxersen, and Ulefnersen, targeting various diseases, including hepatitis B virus and rare genetic neurological disorders.
From a financial perspective, Ionis Pharmaceuticals has a market capitalization of approximately $6.68 billion. The companys forward Price-to-Earnings ratio is around 90.91, indicating a high growth expectation. Return on Equity is negative, at -92.06, suggesting significant investment in research and development. Key Performance Indicators (KPIs) to monitor include revenue growth, R&D expenses as a percentage of revenue, and the number of new product approvals.
Ionis Pharmaceuticals has established strategic collaborations with major pharmaceutical companies, including Biogen, GSK, AstraZeneca, Novartis, and Roche, to develop treatments for neurological disorders and other diseases. These partnerships can help mitigate development risks and costs, while also providing access to additional resources and expertise.
IONS Stock Overview
| Market Cap in USD | 10,201m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1991-05-17 |
IONS Stock Ratings
| Growth Rating | 30.0% |
| Fundamental | 36.7% |
| Dividend Rating | 0.21% |
| Return 12m vs S&P 500 | 24.3% |
| Analyst Rating | 4.08 of 5 |
IONS Dividends
Currently no dividends paidIONS Growth Ratios
| Growth Correlation 3m | 74.5% |
| Growth Correlation 12m | 23.3% |
| Growth Correlation 5y | -10.3% |
| CAGR 5y | 10.82% |
| CAGR/Max DD 3y | 0.21 |
| CAGR/Mean DD 3y | 0.57 |
| Sharpe Ratio 12m | 0.22 |
| Alpha | 0.04 |
| Beta | 0.683 |
| Volatility | 41.36% |
| Current Volume | 1636.4k |
| Average Volume 20d | 2003.8k |
| Stop Loss | 58.7 (-4%) |
| Signal | -0.17 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-268.2m TTM) > 0 and > 6% of Revenue (6% = 56.7m TTM) |
| FCFTA -0.18 (>2.0%) and ΔFCFTA -5.83pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 177.9% (prev 248.8%; Δ -70.87pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.08 (>3.0%) and CFO -230.6m > Net Income -268.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (182.3m) change vs 12m ago 24.92% (target <= -2.0% for YES) |
| Gross Margin 98.89% (prev 97.22%; Δ 1.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.27% (prev 30.22%; Δ 3.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.36 (EBITDA TTM -188.4m / Interest Expense TTM 89.8m) >= 6 (WARN >= 3) |
Altman Z'' -0.32
| (A) 0.56 = (Total Current Assets 2.58b - Total Current Liabilities 897.2m) / Total Assets 2.99b |
| (B) -0.76 = Retained Earnings (Balance) -2.27b / Total Assets 2.99b |
| (C) -0.07 = EBIT TTM -211.7m / Avg Total Assets 2.84b |
| (D) -0.98 = Book Value of Equity -2.30b / Total Liabilities 2.35b |
| Total Rating: -0.32 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.71
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -5.96% = -2.98 |
| 3. FCF Margin -57.85% = -7.50 |
| 4. Debt/Equity 1.99 = 0.79 |
| 5. Debt/Ebitda -6.66 = -2.50 |
| 6. ROIC - WACC data missing |
| 7. RoE -45.49% = -2.50 |
| 8. Rev. Trend 38.88% = 2.92 |
| 9. EPS Trend 39.74% = 1.99 |
What is the price of IONS shares?
Over the past week, the price has changed by -4.42%, over one month by +40.85%, over three months by +69.21% and over the past year by +47.36%.
Is Ionis Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IONS is around 55.57 USD . This means that IONS is currently overvalued and has a potential downside of -9.15%.
Is IONS a buy, sell or hold?
- Strong Buy: 12
- Buy: 5
- Hold: 8
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the IONS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.6 | 12.1% |
| Analysts Target Price | 68.6 | 12.1% |
| ValueRay Target Price | 62 | 1.3% |
Last update: 2025-09-12 04:38
IONS Fundamental Data Overview
CCE Cash And Equivalents = 2.29b USD (Cash And Short Term Investments, last quarter)
P/E Forward = 90.9091
P/S = 10.8056
P/B = 16.1479
P/EG = 25.7033
Beta = 0.278
Revenue TTM = 944.2m USD
EBIT TTM = -211.7m USD
EBITDA TTM = -188.4m USD
Long Term Debt = 625.5m USD (from longTermDebt, last quarter)
Short Term Debt = 630.1m USD (from shortTermDebt, last quarter)
Debt = 1.26b USD (Calculated: Short Term 630.1m + Long Term 625.5m)
Net Debt = 1.12b USD (from netDebt column, last quarter)
Enterprise Value = 9.17b USD (10.20b + Debt 1.26b - CCE 2.29b)
Interest Coverage Ratio = -2.36 (Ebit TTM -211.7m / Interest Expense TTM 89.8m)
FCF Yield = -5.96% (FCF TTM -546.2m / Enterprise Value 9.17b)
FCF Margin = -57.85% (FCF TTM -546.2m / Revenue TTM 944.2m)
Net Margin = -28.41% (Net Income TTM -268.2m / Revenue TTM 944.2m)
Gross Margin = 98.89% ((Revenue TTM 944.2m - Cost of Revenue TTM 10.5m) / Revenue TTM)
Tobins Q-Ratio = -3.98 (set to none) (Enterprise Value 9.17b / Book Value Of Equity -2.30b)
Interest Expense / Debt = 1.81% (Interest Expense 22.8m / Debt 1.26b)
Taxrate = -0.02% (set to none) (-20.0k / 123.5m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.87 (Total Current Assets 2.58b / Total Current Liabilities 897.2m)
Debt / Equity = 1.99 (Debt 1.26b / last Quarter total Stockholder Equity 631.7m)
Debt / EBITDA = -6.66 (Net Debt 1.12b / EBITDA -188.4m)
Debt / FCF = -2.30 (Debt 1.26b / FCF TTM -546.2m)
Total Stockholder Equity = 589.6m (last 4 quarters mean)
RoA = -8.99% (Net Income -268.2m, Total Assets 2.99b )
RoE = -45.49% (Net Income TTM -268.2m / Total Stockholder Equity 589.6m)
RoCE = -17.42% (Ebit -211.7m / (Equity 589.6m + L.T.Debt 625.5m))
RoIC = unknown (NOPAT none, Invested Capital 1.85b, Ebit -211.7m)
WACC = unknown (E(10.20b)/V(11.46b) * Re(8.53%)) + (D(1.26b)/V(11.46b) * Rd(1.81%) * (1-Tc(none)))
Shares Correlation 3-Years: 100.00 | Cagr: 2.30%
Discount Rate = 8.53% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -546.2m)
EPS Correlation: 39.74 | EPS CAGR: 26.99% | SUE: 3.69 | # QB: 1
Revenue Correlation: 38.88 | Revenue CAGR: 45.97% | SUE: 4.0 | # QB: 1
Additional Sources for IONS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle